Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

TransMedics (TMDX) EBIAT (2018 - 2025)

TransMedics has reported EBIAT over the past 8 years, most recently at $105.4 million for Q4 2025.

  • Quarterly results put EBIAT at $105.4 million for Q4 2025, up 1437.0% from a year ago — trailing twelve months through Dec 2025 was $190.3 million (up 436.6% YoY), and the annual figure for FY2025 was $190.3 million, up 436.6%.
  • EBIAT for Q4 2025 was $105.4 million at TransMedics, up from $24.3 million in the prior quarter.
  • Over the last five years, EBIAT for TMDX hit a ceiling of $105.4 million in Q4 2025 and a floor of -$25.4 million in Q3 2023.
  • Median EBIAT over the past 5 years was -$1.8 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in EBIAT: tumbled 242.34% in 2023 and later skyrocketed 1437.0% in 2025.
  • TransMedics' EBIAT stood at -$12.7 million in 2021, then surged by 46.95% to -$6.7 million in 2022, then soared by 159.99% to $4.0 million in 2023, then soared by 70.11% to $6.9 million in 2024, then skyrocketed by 1437.0% to $105.4 million in 2025.
  • The last three reported values for EBIAT were $105.4 million (Q4 2025), $24.3 million (Q3 2025), and $34.9 million (Q2 2025) per Business Quant data.